Think of pharma’s new outreach to patient groups as Patient Advocacy 3.0 – a new set of relationships designed to impact the early stages of drug development by defining the targets and criteria for drug review and approval by the Food & Drug Administration.
Patient Advocacy 1.0 stretches back about twenty five years to the early push for accelerated approval approaches for HIV treatments, expanded to put more pressure on FDA to meet timelines...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?